Thrombocytopenic purpura following COVID-19 vaccination

Abstract

Introduction: The COVID-19 pandemic has generated an inexorable cost to governments and a high mortality in general terms, the vaccination process is the only effective strategy to reduce morbidity and mortality in general, however such administration is not without risks.

Presentation of the case: We present the clinical case of a female patient of the seventh decade who is vaccinated against covid 19 and after 4 days after the second dose of vaccine against COVID 19 begins to present purple lesions that start in the lower limbs and progressively ascend to the trunk associated with intense arthralgias, abdominal pain and nausea, she is admitted finding platelet counts lower than 10,000 platelets, the diagnosis of an immune thrombocytopenic purpura associated with the ASTRAZENECA vaccine against COVID-19 is initiated, initiating specific immunosuppressive therapy.

Discussion: The present case constitutes the appearance of an idiopathic thrombocytopenic purpura, a rare pathology with a wide repertoire of triggering events, infections and vaccine reactions being among the main triggers. The present vaccine reaction is rare, the anecdotal being specifically the presence of immune thrombocytopenic purpura, so far there are very few descriptions in the literature about this type of vaccine reaction, which is why was decided to collect and publish it, mentioning the most recent scientific evidence available on the subject.